Circulating sphingosine-1-phosphate as a prognostic biomarker for community-acquired pneumonia

• DOI: 10.1371/journal.pone.0216963
• Publication Date: 2019-05-15T17:31:03Z
• Authors: Shih-Chang Hsu; Jer-Hwa Chang; Yuan-Pin Hsu; Kuan-Jen Bai; Shau-Ku Huang; Chin-Wang Hsu
• Keywords: Male; 0301 basic medicine; 0303 health sciences; Science; Q; R; Pilot Projects; Pneumonia; Middle Aged; Prognosis; 3. Good health; Community-Acquired Infections; Hospitalization; Intensive Care Units; 03 medical and health sciences; Logistic Models; Sphingosine; Medicine; Humans; Female; Lysophospholipids; Emergency Service, Hospital; Biomarkers; Research Article; Aged

Early determination of the severity Community-Acquired Pneumonia (CAP) is essential for better disease prognosis. Current predictors are suboptimal, and their clinical utility remains to be defined, highlighting need developing biomarkers with efficacious prognostic value. Sphingosine-1-phosphate (S1P) a bioactive sphingolipid documented regulatory role in immune defense maintenance endothelial barrier integrity. For early diagnose CAP recognition severe patients, we conduct this pilot study access potential circulating S1P an Emergency department setting. In prospective study, plasma levels were quantified healthy controls patients CAP. Also, discriminating power was assessed by receiver operating characteristic analysis. The association between indices Spearman correlation logistic regression tests. Patients had significantly higher than individuals (CAP: 27.54 ng/ml, IQR = 14.37–49.99 ng/ml; Controls: 10.58 4.781–18.91 p < 0.0001). inversely correlated Based on multivariate analysis, concentrations showed significant predicting mortality (OR: 0.909; CI: 0.801–0.985; 0.05), intensive care unit admission 0.89; 0.812–0.953; 0.005) long hospital stay 0.978; 0.961–0.992; 0.005). Interestingly, elevated noted who received methylprednisolone treatment during hospitalization. These results suggest that may associated pathogenesis have its therapy, especially Department